BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9752299)

  • 21. Progesterone and estrogen receptors as prognostic variables in breast cancer.
    Mason BH; Holdaway IM; Mullins PR; Yee LH; Kay RG
    Cancer Res; 1983 Jun; 43(6):2985-90. PubMed ID: 6850609
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The importance of prognostic factors in premenopausal women with breast cancer.
    Finek J; Holubec L; Topolcan O; Elgrova L; Skalova A; Pecen L
    Anticancer Res; 2007; 27(4A):1893-6. PubMed ID: 17649790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
    Yu H; Levesque MA; Clark GM; Diamandis EP
    Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic markers in node-negative breast cancer: a prospective study.
    Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
    Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
    Guarneri V; Broglio K; Kau SW; Cristofanilli M; Buzdar AU; Valero V; Buchholz T; Meric F; Middleton L; Hortobagyi GN; Gonzalez-Angulo AM
    J Clin Oncol; 2006 Mar; 24(7):1037-44. PubMed ID: 16505422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
    Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
    J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ascertaining prognosis for breast cancer in node-negative patients with innovative survival analysis.
    Chapman JA; Lickley HL; Trudeau ME; Hanna WM; Kahn HJ; Murray D; Sawka CA; Mobbs BG; McCready DR; Pritchard KI
    Breast J; 2006; 12(1):37-47. PubMed ID: 16409585
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cancer of the breast and the receptor status].
    Buonomo O; Serao A; Muggianu A; Guglielmelli E; Davoli E; Amori A
    G Chir; 1991 Apr; 12(4):274-7. PubMed ID: 1911078
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
    J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients.
    Gasparini G; Fox SB; Verderio P; Bonoldi E; Bevilacqua P; Boracchi P; Dante S; Marubini E; Harris AL
    Clin Cancer Res; 1996 Jul; 2(7):1191-8. PubMed ID: 9816287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
    Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
    Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy.
    Takei H; Horiguchi J; Maemura M; Koibuchi Y; Oyama T; Yokoe T; Iino Y; Morishita Y
    Oncol Rep; 2002; 9(2):375-8. PubMed ID: 11836611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers.
    Pichon MF; Broet P; Magdelenat H; Delarue JC; Spyratos F; Basuyau JP; Saez S; Rallet A; Courriere P; Millon R; Asselain B
    Br J Cancer; 1996 Jun; 73(12):1545-51. PubMed ID: 8664127
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Independent prognostic value of laminin receptor expression in breast cancer survival.
    Marques LA; Franco EL; Torloni H; Brentani MM; da Silva-Neto JB; Brentani RR
    Cancer Res; 1990 Mar; 50(5):1479-83. PubMed ID: 2137368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
    el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
    Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer.
    Ouyang Y; Li D; Pater JL; Levine M
    Breast Cancer Res Treat; 2005 Jul; 92(2):115-23. PubMed ID: 15986120
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival.
    Cheang MC; Treaba DO; Speers CH; Olivotto IA; Bajdik CD; Chia SK; Goldstein LC; Gelmon KA; Huntsman D; Gilks CB; Nielsen TO; Gown AM
    J Clin Oncol; 2006 Dec; 24(36):5637-44. PubMed ID: 17116944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
    Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F
    Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The significance of hormone receptor content in primary tumors for cytostatic therapy of advanced breast carcinoma].
    Petru E; Beck K; Schünemann H; Schmähl D
    Wien Med Wochenschr; 1991; 141(7):133-5. PubMed ID: 2058160
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of results of estrogen and progesterone receptor assays performed in a community hospital.
    Szakacs JG; Arroyo JG; Girgenti AJ
    Ann Clin Lab Sci; 1986; 16(4):266-73. PubMed ID: 3740795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.